Abraxane News and Research

RSS
The U.S. Food and Drug Administration approved Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
Study reveals new role for cancer drug in tumor immunology

Study reveals new role for cancer drug in tumor immunology

Halozyme Therapeutics doses first patient in Halo-301 | Pancreatic study

Halozyme Therapeutics doses first patient in Halo-301 | Pancreatic study

Oasmia Pharmaceutical’s Paclical is bioequivalent of Celgene’s Abraxane in treatment of women with metastatic breast cancer

Oasmia Pharmaceutical’s Paclical is bioequivalent of Celgene’s Abraxane in treatment of women with metastatic breast cancer

Oasmia Pharmaceutical’s Paclical is bioequivalent of Celgene’s Abraxane in treatment of women with metastatic breast cancer

Oasmia Pharmaceutical’s Paclical is bioequivalent of Celgene’s Abraxane in treatment of women with metastatic breast cancer

OncoGenex reports results from Phase 2 Rainier study in patients with untreated metastatic pancreatic cancer

OncoGenex reports results from Phase 2 Rainier study in patients with untreated metastatic pancreatic cancer

Molecular packaging enhances cancer drug’s effectiveness at destroying tumors

Molecular packaging enhances cancer drug’s effectiveness at destroying tumors

Oasmia announces topline results from head-to-head comparison study of Paclical and Abraxane

Oasmia announces topline results from head-to-head comparison study of Paclical and Abraxane

Sorrento, NantBioScience form joint venture to develop targeted therapies against cancer

Sorrento, NantBioScience form joint venture to develop targeted therapies against cancer

Halozyme announces positive Phase 2 results of PEGPH20 drug for treating metastatic pancreatic cancer patients

Halozyme announces positive Phase 2 results of PEGPH20 drug for treating metastatic pancreatic cancer patients

Ventana, Halozyme partner to develop companion diagnostic assay for cancer treatment

Ventana, Halozyme partner to develop companion diagnostic assay for cancer treatment

UQDI reveals that Anisina drug can kill melanoma cells

UQDI reveals that Anisina drug can kill melanoma cells

NantWorks, Sorrento collaborate to discover and develop novel anti-cancer immunotherapies

NantWorks, Sorrento collaborate to discover and develop novel anti-cancer immunotherapies

Halozyme's PEGPH20 receives FDA Orphan Drug designation for treatment of pancreatic cancer

Halozyme's PEGPH20 receives FDA Orphan Drug designation for treatment of pancreatic cancer

NantHealth to unveil open Clinical Operating System at NHS Confederation Annual Conference and Exhibition

NantHealth to unveil open Clinical Operating System at NHS Confederation Annual Conference and Exhibition

Sorrento Therapeutics prices underwritten public offering of 4,765,000 shares of common stock

Sorrento Therapeutics prices underwritten public offering of 4,765,000 shares of common stock

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

New research assesses nanomedicine-based approaches for treating cancer

New research assesses nanomedicine-based approaches for treating cancer

Romidepsin drug shows surprising benefit in preclinical studies of inflammatory breast cancer

Romidepsin drug shows surprising benefit in preclinical studies of inflammatory breast cancer

CHMP adopts positive opinion for ABRAXANE with gemcitabine for treatment of metastatic pancreas

CHMP adopts positive opinion for ABRAXANE with gemcitabine for treatment of metastatic pancreas

NTU establishes new $60 million research institute in Nanomedicine

NTU establishes new $60 million research institute in Nanomedicine